BioRestorative Therapies (BRTX) Securities (2022 - 2025)

BioRestorative Therapies (BRTX) has reported Securities for 4 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Securities fell 85.84% year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $1.4 million (down 85.84% YoY), and the FY2025 full-year result was $1.4 million, down 85.84% from the prior year.
• Securities declined to $1.4 million in Q4 2025 per BRTX's latest filing, from $10.2 million in the prior quarter.
• Across five years, Securities topped out at $13.0 million in Q4 2022 and bottomed at $1.4 million in Q4 2025.
• Historically, Securities has averaged $8.7 million across 4 years, with a median of $10.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Securities climbed 0.03% in 2024, then tumbled 85.84% in 2025.
• Over 4 years, Securities stood at $13.0 million in 2022, then slipped by 21.89% to $10.2 million in 2023, then gained by 0.03% to $10.2 million in 2024, then plunged by 85.84% to $1.4 million in 2025.
• According to Business Quant data, Securities over the past three periods registered $1.4 million, $10.2 million, and $10.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.